CHRS:NSD-Coherus BioSciences, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.62

Change

0.00 (0.00)%

Market Cap

USD 1.34B

Volume

0.34M

Average Target Price

USD 29.00 (+55.75%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD58.95B 22.22 16.42
REGN Regeneron Pharmaceuticals, Inc

N/A

USD54.85B 18.84 14.36
MRNA Moderna, Inc

N/A

USD50.27B N/A N/A
SGEN Seagen Inc

N/A

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

N/A

USD27.10B 28.74 26.73
RPRX Royalty Pharma plc

N/A

USD26.01B 22.60 9.61
BNTX BioNTech SE

N/A

USD25.27B -99,999.99 N/A
BGNE BeiGene, Ltd

N/A

USD25.02B N/A N/A
GMAB Genmab A/S

N/A

USD23.59B 26.59 2.65
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CHRS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.42% 49% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.42% 49% F 52% F
Trailing 12 Months  
Capital Gain 3.50% 45% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.50% 44% F 49% F
Trailing 5 Years  
Capital Gain -38.69% 47% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.69% 47% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain 5.19% N/A N/A 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.19% N/A N/A 49% F
Risk Return Profile  
Volatility (Standard Deviation) 40.23% N/A N/A 31% F
Risk Adjusted Return 12.91% N/A N/A 41% F
Market Capitalization 1.34B 78% C+ 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 9.07 47% F 78% C+
Price/Book Ratio 5.09 42% F 27% F
Price / Cash Flow Ratio 47.31 2% F 8% F
EV/EBITDA 6.40 36% F 80% B-
Management Effectiveness  
Return on Equity 103.78% 100% A+ 100% A+
Return on Invested Capital 60.23% 97% A+ 98% A+
Return on Assets 20.45% 100% A+ 99% A+
Debt to Equity Ratio 169.55% 14% F 12% F
Technical Ratios  
Short Ratio 17.26 8% F 4% F
Short Percent 26.95% 4% F 7% F
Beta 1.69 40% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.